Cardiology in Connecticut

BioWave Corporation manufactures FDA-cleared neuromodulation devices for non-invasive pain management and functional recovery. The company specializes in high-frequency peripheral nerve stimulation (HFPNS) technology that delivers therapeutic stimulation directly to pain nerves, blocking pain signal transmission at the source rather than masking surface pain. BioWave's product line includes portable, easy-to-use devices for clinical and home use, complemented by professional in-office procedures. Products include BioWavePRO (professional clinical system), BioWaveHOME (home-use device), BioWaveGO (portable system), BioWavePENS (in-office procedure delivering up to 72 hours of relief in a 30-minute session), and consumable electrodes (noninvasive and percutaneous). Clinical evidence demonstrates meaningful pain reduction, improved mobility and activities of daily living, reduced medication dependency, and high patient satisfaction. The technology is prescribed by the Veterans Administration for tens of thousands of veterans managing chronic and acute pain. BioWave devices are indicated for use in orthopedic, sports medicine, workers' compensation, personal injury, and auto insurance settings. The company serves patients, healthcare providers, sports medicine teams, and distribution partners. Devices are non-surgical, drug-free, and safe for continuous home use with automatic shut-off. Coverage is available through multiple insurance pathways including Workers' Compensation and Personal Injury claims.

MannKind Corporation is a biopharmaceutical company focused on innovative drug delivery technologies, particularly inhaled therapies for chronic diseases. Founded in 1991 and headquartered in Danbury, Connecticut, MannKind specializes in treatments for cardiometabolic diseases, orphan lung diseases, pulmonary hypertension, and fluid overload in heart and chronic kidney disease. The company utilizes its proprietary Technosphere® platform for pulmonary drug delivery. Key marketed products include Afrezza® (inhaled insulin for diabetes), V-Go® (all-in-one insulin delivery patch), FUROSCIX® (furosemide injection for fluid overload), and Tyvaso DPI® (treprostinil inhalation powder for pulmonary hypertension, utilizing Technosphere technology under partnership with United Therapeutics). MannKind is committed to enhancing patient outcomes through transformative therapies and ongoing clinical development across endocrine and orphan lung disease indications.